This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

BioMarin-Amicus file US antitrust paperwork, make EU referral request

( February 2, 2026, 14:05 GMT | Official Statement) -- MLex Summary: BioMarin Pharmaceutical and Amicus Therapeutics have filed paperwork with the US antitrust authorities on Jan. 21, triggering a deadline under the Hart-Scott-Rodino Act for Feb. 20, according to an Amicus US Securities and Exchange Commission filing. Amicus also said in the filing that BioMarin made a referral request to the European Commission for review of the transaction. Extract. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login